An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)
Latest Information Update: 24 May 2024
At a glance
- Drugs Blinatumomab (Primary) ; Venetoclax (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 May 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2025.
- 21 May 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2025.
- 12 Dec 2023 First Results (n=7)presented at the 65th American Society of Hematology Annual Meeting and Exposition